Equities

Solventum Corp

Solventum Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)72.37
  • Today's Change0.235 / 0.33%
  • Shares traded228.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 16:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Solventum Corp. is a global healthcare company. Its segments include Medical Surgical, Dental Solutions, Health Information Systems, and Purification and Filtration. Medical Surgical is a provider of solutions including advanced wound care, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. Dental Solutions provides dental and orthodontic products include brackets, aligners, restorative cements, and bonding agents that span the life of the tooth, including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs. Health Information Systems offers healthcare systems with software solutions, including computer-assisted physician documentation, direct-to-bill and coding automation, speech recognition, and data visualization platforms. Purification and Filtration is a provider of purification and filtration technologies including filters, purifiers, cartridges, and membranes.

  • Revenue in USD (TTM)8.21bn
  • Net income in USD1.06bn
  • Incorporated2023
  • Employees22.01k
  • Location
    Solventum CorpC/O 3M Company3M Center, Building 275-6W-02ST. PAUL 55144-1000United StatesUSA
  • Phone+1 (651) 733-1110
  • Fax+1 (302) 636-5454
  • Websitehttps://www.solventum.com/en-us/home/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PACS Group Inc-100.00bn-100.00bn6.33bn32.43k--10.87----------3.75----------------------------0.4792--28.47---25.00------
Acadia Healthcare Company Inc3.06bn-5.12m7.24bn23.50k--2.4249.922.37-0.0725-0.072533.3732.210.5647--8.32179,836.800.07052.320.07922.64----0.12495.601.175.440.3754--12.208.99-107.93--3.34--
Ensign Group Inc3.97bn225.40m8.62bn35.30k38.695.2028.392.173.903.9068.7529.050.9458--7.99112,397.305.396.456.437.8821.3622.325.696.48--354.480.08156.5623.2716.28-6.8028.624.405.02
Chemed Corp2.34bn300.92m8.69bn15.09k29.307.1723.933.7219.7219.72153.0180.511.44133.4215.30154,805.9018.5719.5322.4924.6435.9634.6012.8812.601.73--0.008.156.064.909.175.801.466.10
Encompass Health Corp5.07bn409.00m9.30bn22.36k23.035.0611.481.834.013.8949.7818.280.8279--9.04226,825.008.656.3711.017.9495.4995.5810.459.16--5.900.517830.7810.412.3441.314.4916.60-10.42
Solventum Corp8.21bn1.06bn12.46bn22.01k11.774.357.721.526.136.1347.5016.600.58173.977.36372,926.807.50--8.72--56.98--12.89--0.958410.030.7434--0.8241--0.2234------
Davita Inc12.52bn859.62m13.69bn70.00k17.3621.937.231.099.409.40136.767.440.737171.095.81178,919.406.745.629.107.4532.7230.709.158.331.125.260.7876--4.571.2626.442.33-10.47--
Tenet Healthcare Corp20.92bn2.76bn15.43bn78.14k5.894.443.520.737927.3227.32205.2636.270.74149.276.85267,659.7012.523.6118.255.0982.5882.9716.894.951.384.890.62060.007.172.3349.0241.424.01--
Universal Health Services, Inc.15.02bn934.19m15.50bn73.35k17.212.4110.201.0313.6313.63218.7797.211.08--7.05204,737.606.826.448.077.63----6.316.551.176.910.40946.066.595.806.32-1.471.1714.87
Natera Inc1.36bn-292.12m15.72bn3.28k--18.74--11.55-2.47-2.4711.386.780.984115.014.57414,534.80-21.13-36.17-26.88-46.6053.8545.88-21.47-56.154.01--0.3032--31.9933.2620.63--58.81--
Quest Diagnostics Inc9.35bn836.00m17.31bn40.00k20.972.6113.101.857.417.4182.8959.610.684534.237.32233,650.006.369.287.4910.8132.9836.649.2912.970.9128.510.396325.07-6.384.20-9.773.401.277.43
Data as of Sep 19 2024. Currency figures normalised to Solventum Corp's reporting currency: US Dollar USD

Institutional shareholders

30.69%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202415.68m9.08%
BlackRock Fund Advisorsas of 30 Jun 20247.36m4.26%
SSgA Funds Management, Inc.as of 30 Jun 20245.92m3.43%
Trian Fund Management LPas of 30 Jun 20245.36m3.10%
Davis Selected Advisers LPas of 30 Jun 20245.16m2.99%
Geode Capital Management LLCas of 30 Jun 20243.22m1.86%
Invesco Capital Management LLCas of 30 Jun 20243.05m1.77%
Norges Bank Investment Managementas of 30 Jun 20242.59m1.50%
Madison Avenue Partners LPas of 30 Jun 20242.46m1.43%
Nuance Investments LLCas of 30 Jun 20242.19m1.27%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.